Article
Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models.
Molecular cancer therapeutics - 2 Dec 2022
Tran Khanh B, Kolekar Sharada, Wang Qian, Shih Jen-Hsing, Buchanan Christina M, Deva Sanjeev, Shepherd Peter R
Abstract excerpt
The fact that 10% of colorectal cancer tumors harbor BRAF V600E mutations suggested targeting BRAF as a potential therapy. However, BRAF inhibitors have only limited single-agent efficacy in this context. The potential for combination therapy has been shown by the BEACON trial where targeting the EGF receptor with cetuximab greatly increased efficacy of BRAF inhibitors in BRAF-mutant colorectal cancer. Therefore,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.